Use of oral glutamine in radiation-induced adverse effects in patients with thoracic and upper aerodigestive malignancies: Results of a prospective observational study

Amalia Papanikolopoulou, Nikolaos Syrigos, Louisa Vini, Maria Papasavva, Georgios Lazopoulos, Stelios Kteniadakis, Demetrios A Spandidos, Adrianni Charpidou, Nikolaos Drakoulis, Amalia Papanikolopoulou, Nikolaos Syrigos, Louisa Vini, Maria Papasavva, Georgios Lazopoulos, Stelios Kteniadakis, Demetrios A Spandidos, Adrianni Charpidou, Nikolaos Drakoulis

Abstract

Cancer growth in host tissues features glutamine (gln) depletion over time, decreasing epithelial cells' optimal functioning. In addition, radiotherapy (RT) and/or chemotherapy (CT) cause damage to normal tissues, probably enhanced by this depletion. The present study prospectively examined the effect of gln supplementation on 72 patients with thoracic and upper aerodigestive malignancies (T&UAM) treated with sequential or concurrent RT-CT or RT alone. All patients received prophylactic gln powder 15 g bid for the full duration of treatment. The severity of acute radiation toxicities was graded according to the RT Oncology Group/European Organization for Research and Treatment of Cancer criteria. Primary endpoints were the incidence of grade >2 toxicities, weight loss and requirement for analgesics, and the secondary endpoint was the association of the length of irradiated esophagus from treatment planning with the use of opioids. The incidence of adverse effects was as follows: Grade >2 stomatitis, 25.0%; esophagitis, 60.5%; dysphagia, 54.2%; pain, 25.4%; mycosis, 40.8%. Stomatitis grade >2 was more frequent in patients with head and neck tumors (P<0.001) and in those with prior surgery (P<0.001). Esophagitis (P=0.020) and dysphagia (P=0.008) grade >2 were more frequent in patients with concurrent RT-CT. Regarding analgesics, 9.9% of patients received no pain treatment, 56.3% received simple analgesic therapy and 33.8% opioids. Patients on opioid therapy had a greater mean length of irradiated esophagus (P=0.024) or length >12 cm (P=0.018). In 54.2% of patients, weight loss was observed, particularly with concurrent RT-CT (P=0.007). Thus, the use of oral gln may have an important role in reducing acute radiation toxicities and weight loss, and in lowering the requirement for analgesics in patients with T&UAM. Further randomized trials are required to identify the appropriate gln dose, duration of treatment and precise radiation dosimetric parameters in this group of patients. The present clinical trial was retrospectively registered in the ClinicalTrials.gov Protocol Registration and Results System (registration no. NCT05054517/22-09-2021).

Keywords: chest tumor; clinical study; glutamine; head and neck cancer; human subjects; lung cancer.

Conflict of interest statement

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

Copyright: © Papanikolopoulou et al.

Figures

Figure 1.
Figure 1.
Medical oncology significance of gln. Gln has effects on mucositis/stomatitis, esophagitis, diarrhea, weight loss, gut permeability, lymphocyte count, hospital stay and pain. Gln, glutamine; GSH, glutathione.
Figure 2.
Figure 2.
Acute RT-induced adverse events and type of treatment. Percentages of acute adverse events in 72 patients with T&UAM who took oral gln powder at doses of 15 g 2 times per day for the total duration of radiation treatment. T&UAM, thoracic and upper aerodigestive malignancies; RT, radiotherapy; gln, glutamine.

References

    1. DeBerardinis RJ, Cheng T. Q's next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29:313–324. doi: 10.1038/onc.2009.358.
    1. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330:1340–1344. doi: 10.1126/science.1193494.
    1. Barger JF, Plas DR. Balancing biosynthesis and bioenergetics: Metabolic programs in oncogenesis. Endocr Relat Cancer. 2010;17:R287–R304. doi: 10.1677/ERC-10-0106.
    1. Cantor JR, Sabatini DM. Cancer cell metabolism: One hallmark, many faces. Cancer Discov. 2012;2:881–898. doi: 10.1158/-12-0345.
    1. Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW-M, Phang JM. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA. 2012;109:8983–8988. doi: 10.1073/pnas.1203244109.
    1. Chen JQ, Russo J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim Biophys Acta. 2012;1826:370–384.
    1. Kuhn KS, Muscaritoli M, Wischmeyer P, Stehle P. Glutamine as indispensable nutrient in oncology: Experimental and clinical evidence. Eur J Nutr. 2010;49:197–210. doi: 10.1007/s00394-009-0082-2.
    1. Polet F, Feron O. Endothelial cell metabolism and tumour angiogenesis: Glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med. 2013;273:156–165. doi: 10.1111/joim.12016.
    1. Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther. 1990;46:243–271. doi: 10.1016/0163-7258(90)90094-I.
    1. Rubio IT, Cao Y, Hutchins LF, Westbrook KC, Klimberg VS. Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg. 1998;227:772–778. doi: 10.1097/00000658-199805000-00018. discussion 778–780.
    1. Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer. 2017;3:169–180. doi: 10.1016/j.trecan.2017.01.005.
    1. Choi YK, Park KG. Targeting Glutamine Metabolism for Cancer Treatment. Biomol Ther (Seoul) 2018;26:19–28. doi: 10.4062/biomolther.2017.178.
    1. Anderson PM, Lalla RV. Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy. Nutrients. 2020;12:1675. doi: 10.3390/nu12061675.
    1. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29:501–513. doi: 10.1016/S0305-7372(03)00133-6.
    1. Papanikolopoulou A, Syrigos KN, Drakoulis N. The role of glutamine supplementation in thoracic and upper aerodigestive malignancies. Nutr Cancer. 2015;67:231–237. doi: 10.1080/01635581.2015.990572.
    1. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys. 1995;31:1341–1346. doi: 10.1016/0360-3016(95)00060-C.
    1. Subramaniam AV, Salem Yehya AH, Oon CE. Molecular Basis of Cancer Pain Management: An Updated Review. Medicina (Kaunas) 2019;55:584. doi: 10.3390/medicina55090584.
    1. van den Berg H. Asparaginase revisited. Leuk Lymphoma. 2011;52:168–178. doi: 10.3109/10428194.2010.537796.
    1. Jaffe N, Traggis D, Das L, Moloney WC, Hann HW, Kim BS, Nair R. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res. 1971;31:942–949.
    1. Jia ZY, Shen TY, Jiang W, Qin HL. Identification of molecular mechanisms of glutamine in pancreatic cancer. Oncol Lett. 2017;14:6395–6402.
    1. Stanciu AE, Zamfir-Chiru-Anton A, Stanciu MM, Stoian AP, Jinga V, Nitipir C, Bucur A, Pituru TS, Arsene AL, Dragoi CM, et al. Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. Oncol Lett. 2020;19:1537–1543.
    1. Olaru OT, Venables L, VAN DE Venter M, Nitulescu GM, Margina D, Spandidos DA, Tsatsakis AM. Anticancer potential of selected Fallopia Adans species. Oncol Lett. 2015;10:1323–1332. doi: 10.3892/ol.2015.3453.
    1. Pavlova NN, Hui S, Ghergurovich JM, Fan J, Intlekofer AM, White RM, Rabinowitz JD, Thompson CB, Zhang J. As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid. Cell Metab. 2018;27:428–438.e5. doi: 10.1016/j.cmet.2017.12.006.
    1. Bobrovnikova-Marjon EV, Marjon PL, Barbash O, Vander Jagt DL, Abcouwer SF. Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: Role of nuclear factor-kappaB and activating protein-1. Cancer Res. 2004;64:4858–4869. doi: 10.1158/0008-5472.CAN-04-0682.
    1. Ishak Gabra MB, Yang Y, Li H, Senapati P, Hanse EA, Lowman XH, Tran TQ, Zhang L, Doan LT, Xu X, et al. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. Nat Commun. 2020;11:3326. doi: 10.1038/s41467-020-17181-w.
    1. Zhang J, Pavlova NN, Thompson CB. Cancer cell metabolism: The essential role of the nonessential amino acid, glutamine. EMBO J. 2017;36:1302–1315. doi: 10.15252/embj.201696151.
    1. García-de-Lorenzo A, Zarazaga A, García-Luna PP, Gonzalez-Huix F, López-Martínez J, Miján A, Quecedo L, Casimiro C, Usán L, del Llano J. Clinical evidence for enteral nutritional support with glutamine: A systematic review. Nutrition. 2003;19:805–811. doi: 10.1016/S0899-9007(03)00103-5.
    1. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016;91:386–396. doi: 10.1016/j.mayocp.2015.12.017.
    1. Bayman NA, Blackhall F, Jain P, Lee L, Thatcher N, Faivre-Finn C. Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: A review of the current literature and recommendations for treatment. Clin Lung Cancer. 2008;9:92–101. doi: 10.3816/CLC.2008.n.014.
    1. Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, Yeh SA, Hsu HC, Hsiung CY. Oral glutamine to alleviate radiation-induced oral mucositis: A pilot randomized trial. Int J Radiat Oncol Biol Phys. 2000;46:535–539. doi: 10.1016/S0360-3016(99)00402-2.
    1. Sarumathy S, Ismail AM, Palasimany A. Efficacy and safety of oral glutamine in radiation induced oral mucositis in patients with Head and Neck cancer. Asian J Pharm Clin Res. 2012;5:138–140.
    1. Zygogianni A, Kyrgias G, Kouvaris J, Pistevou-Gombaki K, Capezzali G, Zefkili S, Kokkakis J, Georgakopoulos J, Kelekis K, Kouloulias V. Impact of acute radiation induced toxicity of glutamine administration in several hypofractionated irradiation schedules for head and neck carcinoma. Head Neck Oncol. 2012;4:86–92.
    1. Chattopadhyay S, Saha A, Azam M, Mukherjee A, Sur PK. Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis: A prospective randomized study. South Asian J Cancer. 2014;3:8–12. doi: 10.4103/2278-330X.126501.
    1. Tsujimoto T, Yamamoto Y, Wasa M, Takenaka Y, Nakahara S, Takagi T, Tsugane M, Hayashi N, Maeda K, Inohara H, et al. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: A double-blind, randomized, placebo-controlled trial. Oncol Rep. 2015;33:33–39. doi: 10.3892/or.2014.3564.
    1. Pattanayak L, Panda N, Dash MK, Mohanty S, Samantaray S. Management of Chemoradiation-Induced Mucositis in Head and Neck Cancers With Oral Glutamine. J Glob Oncol. 2016;2:200–206. doi: 10.1200/JGO.2015.000786.
    1. Lopez-Vaquero D, Gutierrez-Bayard L, Rodriguez-Ruiz JA, Saldaña-Valderas M, Infante-Cossio P. Double-blind randomized study of oral glutamine on the management of radio/chemotherapy-induced mucositis and dermatitis in head and neck cancer. Mol Clin Oncol. 2017;6:931–936. doi: 10.3892/mco.2017.1238.
    1. Pachón Ibáñez J, Pereira Cunill JL, Osorio Gómez GF, Irles Rocamora JA, Serrano Aguayo P, Quintana Ángel B, Fuentes Pradera J, Chaves Conde M, Ortiz Gordillo MJ, García Luna PP. Prevention of oral mucositis secondary to antineoplastic treatments in head and neck cancer by supplementation with oral glutamine. Nutr Hosp. 2018;35:428–433.
    1. Huang CJ, Huang MY, Fang PT, Chen F, Wang YT, Chen CH, Yuan SS, Huang CM, Luo KH, Chuang HY, et al. Randomized double-blind, placebo-controlled trial evaluating oral glutamine on radiation-induced oral mucositis and dermatitis in head and neck cancer patients. Am J Clin Nutr. 2019;109:606–614. doi: 10.1093/ajcn/nqy329.
    1. Pathak S, Soni TP, Sharma LM, Patni N, Gupta AK. A Randomized Controlled Trial to Evaluate the Role and Efficacy of Oral Glutamine in the Treatment of Chemo-radiotherapy-induced Oral Mucositis and Dysphagia in Patients with Oropharynx and Larynx Carcinoma. Cureus. 2019;11:e4855.
    1. Algara M, Rodríguez N, Viñals P, Lacruz M, Foro P, Reig A, Quera J, Lozano J, Fernández-Velilla E, Membrive I, et al. Prevention of radiochemotherapy-induced esophagitis with glutamine: Results of a pilot study. Int J Radiat Oncol Biol Phys. 2007;69:342–349. doi: 10.1016/j.ijrobp.2007.03.041.
    1. Topkan E, Yavuz MN, Onal C, Yavuz AA. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: Evaluation of clinical and dosimetric parameters. Lung Cancer. 2009;63:393–399. doi: 10.1016/j.lungcan.2008.06.015.
    1. Topkan E, Parlak C, Topuk S, Pehlivan B. Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. BMC Cancer. 2012;12:502–512. doi: 10.1186/1471-2407-12-502.
    1. Gul K, Muge A, Taner A, Sehri E. Oral glutamine supplementation reduces radiotherapy- induced esophagitis in lung cancer patients. Asian Pac J Cancer Prev. 2015;16:53–58. doi: 10.7314/APJCP.2015.16.1.53.
    1. Chang SC, Lai YC, Hung JC, Chang CY. Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer. Medicine (Baltimore) 2019;98:e14463. doi: 10.1097/MD.0000000000014463.
    1. Sayles C, Hickerson SC, Bhat RR, Hall J, Garey KW, Trivedi MV. Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review. Nutr Clin Pract. 2016;31:171–179. doi: 10.1177/0884533615611857.
    1. Leung HW, Chan AL. Glutamine in Alleviation of Radiation-Induced Severe Oral Mucositis: A Meta-Analysis. Nutr Cancer. 2016;68:734–742. doi: 10.1080/01635581.2016.1159700.
    1. Tang G, Huang W, Zhang L, Wei Z. Role of Glutamine in the Management of Oral Mucositis in Patients with Cancer: A Meta-Analysis of Randomized Controlled Trials. Nutr Cancer. 2021;19:1–14. doi: 10.1080/01635581.2021.1957128.
    1. Peng TR, Lin HH, Yang LJ, Wu TW. Correction to: Effectiveness of glutamine in the management of oral mucositis in cancer patients: a meta-analysis of randomized controlled trials. Support Care Cancer. 2021;29:4893. doi: 10.1007/s00520-021-06112-0.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi